Literature DB >> 2168281

Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone.

M E Fox1, P J Smith.   

Abstract

The cytotoxic actions of several classes of antitumor DNA intercalators are thought to result from some disturbance to DNA metabolism following trapping of the nuclear enzyme DNA topoisomerase II as a covalent complex on DNA. Here we have studied topoisomerase II trapping and DNA synthesis patterns in relation to the acute cytotoxic actions of 4'-(9-acridinylamino)methanesulfon-m-anisidide (mAMSA) or mitoxantrone on SV40 transformed human fibroblasts. These two DNA intercalators differed significantly in their cytotoxic potential, mitoxantrone being 24-fold more toxic than mAMSA when assayed by the inhibition of clonogenicity. Although both drugs induced G2 delay at cytotoxic concentrations, mAMSA-treated cells recovered normal cell cycle phase distributions within 24 h of removal of drug, while mitoxantrone-treated cells continued to accumulate in G2 up to 48 h following drug treatment with evidence of complete inhibition of entry into mitosis. Compared with mAMSA, mitoxantrone showed a similar capacity to induce cleavable complexes in cellular DNA, and only a 2-fold greater ability to inhibit DNA synthesis. Within a 4-h posttreatment period, mAMSA-treated cells recovered normal rates of DNA synthesis, whereas a continued depression of DNA synthesis was observed in mitoxantrone-treated cells. The recovery patterns of DNA synthesis correlated with the rapid disappearance of mAMSA-induced complexes (less than 27% lesions remaining 2 h after drug removal) and the persistence of mitoxantrone-induced complexes during a 4-h posttreatment period. This difference in complex longevity was observed in other human transformed fibroblast cell lines irrespective of differences in the absolute levels of complexes induced by either agent. We suggest that the results provide evidence that DNA intercalators may differ in the forms of complexes induced and that the comparatively high cytotoxicity of mitoxantrone relates to the ability of the drug to trap topoisomerase II complexes in a form which effects a long-term inhibition of DNA replication and G2 traverse.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2168281

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors.

Authors:  M Senkal; J C Tonn; R Schönmayr; W Schachenmayr; U Eickhoff; M Kemen; E Kollig
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

2.  Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphtoquinoxaline metabolite, and drug-target complexes.

Authors:  A Feofanov; S Sharonov; F Fleury; I Kudelina; I Nabiev
Journal:  Biophys J       Date:  1997-12       Impact factor: 4.033

3.  Intralesional mitoxantrone biopolymer-mediated chemotherapy prolongs survival in rats with experimental brain tumors.

Authors:  Marco Saini; Florian Roser; Samii Hussein; Madjid Samii; Mattia Bellinzona
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

4.  Mitoxantrone loaded superparamagnetic nanoparticles for drug targeting: a versatile and sensitive method for quantification of drug enrichment in rabbit tissues using HPLC-UV.

Authors:  Rainer Tietze; Eveline Schreiber; Stefan Lyer; Christoph Alexiou
Journal:  J Biomed Biotechnol       Date:  2010-05-13

Review 5.  Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.

Authors:  C J Dunn; K L Goa
Journal:  Drugs Aging       Date:  1996-08       Impact factor: 3.923

6.  Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis.

Authors:  Samuel A Burns; R Lee Archer; Janet A Chavis; Cameron A Tull; Lori L Hensley; Paul D Drew
Journal:  Brain Res       Date:  2012-08-02       Impact factor: 3.252

7.  "Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).

Authors:  G Cimoli; M Valenti; E Noviello; S Parodi; A Mazzoni; E Rovini; F De Sessa; P Russo
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

8.  Quinoline alkaloids as intercalative topoisomerase inhibitors.

Authors:  Kendall G Byler; Chen Wang; William N Setzer
Journal:  J Mol Model       Date:  2009-05-08       Impact factor: 1.810

9.  Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin.

Authors:  G R Fisher; L H Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells.

Authors:  M E Fox; P J Smith
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.